Clinical Trial

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork lamellae spacing, with secondary measures including trabecular meshwork height, width, and Schlemm's canal diameter.
Protocol Amendment History 3 changes
critical Recruitment opened 2026-06-12
notable Primary completion pushed: 2028-05 -> 2028-06 2026-06-12
minor Completion pushed: 2028-05 -> 2028-06 2026-06-12
Trial Details
NCT Number NCT07588152
Lead Sponsor Indiana University
Collaborators: Alcon Research
Conditions Glaucoma, Ocular Hypertension
Enrollment 50 participants
Start Date 2026-06-05
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-06-11